Hydroxamic Acids as Potent Inhibitors of FeII and MnII E. coli Methionine Aminopeptidase: Biological Activities and X‐ray Structures of Oxazole Hydroxamate–EcMetAP‐Mn Complexes

New series of acids and hydroxamic acids linked to five‐membered heterocycles including furan, oxazole, 1,2,4‐ or 1,3,4‐oxadiazole, and imidazole were synthesized and tested as inhibitors against the FeII, CoII, and MnII forms of E. coli methionine aminopeptidase (MetAP) and as antibacterial agents against wild‐type and acrAB E. coli strains. 2‐Aryloxazol‐4‐ylcarboxylic acids appeared as potent and selective inhibitors of the CoII MetAP form, with IC50 values in the micromolar range, whereas 5‐aryloxazol‐2‐ylcarboxylic acid regioisomers and 5‐aryl‐1,2,4‐oxadiazol‐3‐ylcarboxylic acids were shown to be inefficient against all forms of EcMetAP. Regardless of the heterocycle, all the hydroxamic acids are highly potent inhibitors and are selective for the MnII and FeII forms, with IC50 values between 1 and 2 μM. One indole hydroxamic acid that we previously reported as a potent inhibitor of E. coli peptide deformylase also demonstrated efficiency against EcMetAP. To gain insight into the positioning of the oxazole heterocycle with reversed substitutions at positions 2 and 5, X‐ray crystal structures of EcMetAP‐Mn complexed with two such oxazole hydroxamic acids were solved. Irrespective of the [metal]/[apo‐MetAP] ratio, the active site consistently contains a dinuclear manganese center, with the hydroxamate as bridging ligand. Asp 97, which adopts a bidentate binding mode to the Mn2 site in the holoenzyme, is twisted in both structures toward the hydroxamate bridging ligand to favor the formation of a strong hydrogen bond. Most of the compounds show weak antibacterial activity against a wild‐type E. coli strain. However, increased antibacterial activity was observed mainly for compounds with a 2‐substituted phenyl group in the presence of the nonapeptide polymyxin B and phenylalanine–arginine–β‐naphthylamide as permeabilizer and efflux pump blocker, respectively, which boost the intracellular uptake of the inhibitors.

[1]  S. Chai,et al.  A cell-based assay that targets methionine aminopeptidase in a physiologically relevant environment. , 2010, Bioorganic & medicinal chemistry letters.

[2]  A. Kozikowski,et al.  Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles. , 2009, Journal of medicinal chemistry.

[3]  T. Meinnel,et al.  New Antibiotic Molecules: Bypassing the Membrane Barrier of Gram Negative Bacteria Increases the Activity of Peptide Deformylase Inhibitors , 2009, PloS one.

[4]  Anshika Sharma,et al.  Peptide deformylase – a promising therapeutic target for tuberculosis and antibacterial drug discovery , 2009, Expert opinion on therapeutic targets.

[5]  V. Larue,et al.  Structure–Activity Relationship Analysis of the Peptide Deformylase Inhibitor 5‐Bromo‐1H‐indole‐3‐acetohydroxamic Acid , 2009, ChemMedChem.

[6]  S. Mitra,et al.  Analyzing the catalytic role of Asp97 in the methionine aminopeptidase from Escherichia coli , 2008, The FEBS journal.

[7]  S. Mitra,et al.  Kinetic and spectroscopic analysis of the catalytic role of H79 in the methionine aminopeptidase from Escherichia coli. , 2008, Biochemistry.

[8]  S. Chai,et al.  Discovery of inhibitors of Escherichia coli methionine aminopeptidase with the Fe(II)-form selectivity and antibacterial activity. , 2008, Journal of medicinal chemistry.

[9]  S. Chai,et al.  FE(II) Is the Native Cofactor for Escherichia coli Methionine Aminopeptidase* , 2008, Journal of Biological Chemistry.

[10]  F. Nan,et al.  Inhibition of monometalated methionine aminopeptidase: inhibitor discovery and crystallographic analysis. , 2007, Journal of medicinal chemistry.

[11]  Jun O. Liu,et al.  Kinetic and mutational studies of the number of interacting divalent cations required by bacterial and human methionine aminopeptidases. , 2007, Biochemistry.

[12]  V. Larue,et al.  Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. , 2007, Journal of medicinal chemistry.

[13]  Thierry Meinnel,et al.  The Proteomics of N-terminal Methionine Cleavage*S , 2006, Molecular & Cellular Proteomics.

[14]  S. Mitra,et al.  A new colorimetric assay for methionyl aminopeptidases: examination of the binding of a new class of pseudopeptide analog inhibitors. , 2006, Analytical biochemistry.

[15]  S. Xie,et al.  Structural basis of catalysis by monometalated methionine aminopeptidase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  F. Nan,et al.  Metalloform-selective inhibition: synthesis and structure-activity analysis of Mn(II)-form-selective inhibitors of Escherichia coli methionine aminopeptidase. , 2005, Bioorganic & medicinal chemistry letters.

[17]  D. Richardson,et al.  The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer , 2005, Pharmacological Reviews.

[18]  D. Boger,et al.  Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. , 2005, Bioorganic & medicinal chemistry letters.

[19]  S. Xie,et al.  Metalloform-selective inhibitors of escherichia coli methionine aminopeptidase and X-ray structure of a Mn(II)-form enzyme complexed with an inhibitor. , 2004, Journal of the American Chemical Society.

[20]  B. Wessler,et al.  Magnetic circular dichroism and cobalt(II) binding equilibrium studies of Escherichia coli methionyl aminopeptidase. , 2004, Journal of the American Chemical Society.

[21]  K. Nolan,et al.  Hydroxamic Acids − An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands , 2004 .

[22]  T. Meinnel,et al.  Protein N-terminal methionine excision , 2004, Cellular and Molecular Life Sciences CMLS.

[23]  H. Nikaido Molecular Basis of Bacterial Outer Membrane Permeability Revisited , 2003, Microbiology and Molecular Biology Reviews.

[24]  A. Hamilton,et al.  Rigid macrocyclic triamides as anion receptors: anion-dependent binding stoichiometries and 1H chemical shift changes. , 2003, Journal of the American Chemical Society.

[25]  Kexin Yang,et al.  Molecular diversity of hydroxamic acids: part I. Solution- and solid-phase synthesis. , 2003, Mini reviews in medicinal chemistry.

[26]  B. Matthews,et al.  Kinetic and spectroscopic characterization of the H178A methionyl aminopeptidase from Escherichia coli. , 2003, Biochemistry.

[27]  B. Matthews,et al.  Metalloaminopeptidases: common functional themes in disparate structural surroundings. , 2002, Chemical reviews.

[28]  A. Copik,et al.  Kinetic and structural characterization of manganese(II)-loaded methionyl aminopeptidases. , 2002, Biochemistry.

[29]  R. Sindelar,et al.  Hydroxamic acids as pharmacological agents. , 2002, Current medicinal chemistry.

[30]  C. Supuran,et al.  Bacterial protease inhibitors , 2002, Medicinal research reviews.

[31]  Ramesh N. Patel,et al.  Enantioselective microbial reduction of 2-oxo-2-(1′,2′,3′,4′-tetrahydro-1′,1′,4′,4′-tetramethyl-6′-naphthalenyl)acetic acid and its ethyl ester , 2002 .

[32]  N. Cosper,et al.  Structural evidence that the methionyl aminopeptidase from Escherichia coli is a mononuclear metalloprotease. , 2001, Biochemistry.

[33]  David R. Williams,et al.  Synthesis of functionalized oxazolines and oxazoles with DAST and Deoxo-Fluor. , 2000, Organic letters.

[34]  A. Copik,et al.  Divalent metal binding properties of the methionyl aminopeptidase from Escherichia coli. , 2000, Biochemistry.

[35]  K. Wilson,et al.  The complex of Bacillus pasteurii urease with acetohydroxamate anion from X-ray data at 1.55 Å resolution , 2000, JBIC Journal of Biological Inorganic Chemistry.

[36]  E. Barreiro,et al.  Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. , 1999, Farmaco.

[37]  V. D'souza,et al.  The methionyl aminopeptidase from Escherichia coli can function as an iron(II) enzyme. , 1999, Biochemistry.

[38]  B. Matthews,et al.  Escherichia coli methionine aminopeptidase: implications of crystallographic analyses of the native, mutant, and inhibited enzymes for the mechanism of catalysis. , 1999, Biochemistry.

[39]  B. Matthews,et al.  The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B Chevrier,et al.  The structure of the Aeromonas proteolytica aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu151 and two zinc ions of the co-catalytic unit. , 1996, European journal of biochemistry.

[41]  B. Stanovnik,et al.  Nitrosation of methyl 2-acylamino-3-dimethylaminopropenoates. A simple conversion of n-acylglycines into 5-substituted 1,2,4-Oxadiazole-3-carboxylates , 1995 .

[42]  C. Miller,et al.  pepM is an essential gene in Salmonella typhimurium , 1989, Journal of bacteriology.

[43]  S. Chang,et al.  Methionine aminopeptidase gene of Escherichia coli is essential for cell growth , 1989, Journal of bacteriology.

[44]  J. Sauer,et al.  Ringöffnungen der Azole, II. Die Bildung von 1.3.4‐Oxdiazolen bei der Acylierung 5‐substituierter Tetrazole , 1960 .

[45]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[46]  David J. Williams,et al.  Reactions of hydroxylamines with ethyl cyanoformate. Preparation of aminonitrones and their synthetic applications , 1992 .

[47]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.